Does Rinvoq Raise Cholesterol Levels?
Yes, Rinvoq (upadacitinib), a JAK inhibitor for conditions like rheumatoid arthritis and ulcerative colitis, can increase cholesterol levels. Clinical trials showed dose-dependent elevations in low-density lipoprotein (LDL) cholesterol and total cholesterol, often starting within 4-8 weeks and persisting during treatment.[1][2]
How Common Are Cholesterol Changes with Rinvoq?
Lipid increases occur in most patients:
- LDL cholesterol rose by at least 20 mg/dL in 24-36% of patients on 15 mg daily, and up to 45% on higher doses.
- Total cholesterol increases of ≥30 mg/dL affected 35-50% of users.
These shifts are typically asymptomatic but require monitoring, with levels often stabilizing or declining after dose reduction.[1][3]
Why Does Rinvoq Affect Lipids?
Rinvoq inhibits JAK enzymes involved in immune signaling, which also influences lipid metabolism. This leads to higher LDL and HDL cholesterol without major triglyceride changes. The effect is class-wide for JAK inhibitors, linked to reduced LDL receptor activity.[2][4]
What Do Doctors Recommend for Monitoring?
Guidelines advise checking lipid profiles before starting Rinvoq, then 4-8 weeks after initiation and every 6-12 months. Manage elevations with statins if LDL exceeds 100 mg/dL (or 70 mg/dL in high cardiovascular risk patients). Discontinuation is rare unless levels pose acute risk.[1][3]
Who Is at Higher Risk?
Patients with baseline high cholesterol, diabetes, or cardiovascular disease face greater concern. Pre-existing conditions amplify absolute LDL rises, increasing atherosclerosis risk over time.[2][4]
How Does Rinvoq Compare to Other JAK Inhibitors?
Similar lipid effects seen with Xeljanz (tofacitinib) and Olumiant (baricitinib), but Rinvoq may cause slightly larger LDL increases at equivalent doses due to its selectivity for JAK1. Head-to-head data is limited.[4]
Any Long-Term Data or Reversibility?
In extensions up to 5 years, lipid elevations persisted but rarely led to events when managed. Levels often normalize 4-12 weeks after stopping Rinvoq.[1][3]
Sources
[1]: Rinvoq Prescribing Information (AbbVie)
[2]: SELECT Phase 3 Trials (NEJM, 2019-2021)
[3]: FDA Label for Rinvoq
[4]: JAK Inhibitors Lipid Effects Review (Arthritis Rheum, 2022)